{"id":"https://openalex.org/W4281692890","doi":"https://doi.org/10.1111/bcp.15430","title":"Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database","display_name":"Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database","publication_year":2022,"publication_date":"2022-06-04","ids":{"openalex":"https://openalex.org/W4281692890","doi":"https://doi.org/10.1111/bcp.15430","pmid":"https://pubmed.ncbi.nlm.nih.gov/35665950","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9796803"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.15430","doi":"https://doi.org/10.1111/bcp.15430","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15430","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1111/bcp.15430","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025705459","display_name":"Bruno Revol","orcid":"https://orcid.org/0000-0003-2931-2940","observed_orcids":["https://orcid.org/0000-0003-2931-2940"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I2800555055","display_name":"Centre Hospitalier Universitaire de Grenoble","ror":"https://ror.org/041rhpw39","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055"]},{"id":"https://openalex.org/I899635006","display_name":"Universit\u00e9 Grenoble Alpes","ror":"https://ror.org/02rx3b187","country_code":"FR","type":"education","lineage":["https://openalex.org/I899635006"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Bruno Revol","raw_affiliation_strings":["Addictovigilance Department Grenoble Alpes University Hospital  Grenoble France","French Addictovigilance Network (FAN)  France","Inserm Unit 1300, HP2 University Grenoble Alpes  Grenoble France"],"raw_orcid":"https://orcid.org/0000-0003-2931-2940","affiliations":[{"raw_affiliation_string":"Addictovigilance Department Grenoble Alpes University Hospital  Grenoble France","institution_ids":["https://openalex.org/I2800555055"]},{"raw_affiliation_string":"French Addictovigilance Network (FAN)  France","institution_ids":[]},{"raw_affiliation_string":"Inserm Unit 1300, HP2 University Grenoble Alpes  Grenoble France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I899635006"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050870063","display_name":"Maryse Lapeyre\u2010Mestre","orcid":"https://orcid.org/0000-0002-5494-5873","observed_orcids":["https://orcid.org/0000-0002-5494-5873"]},"institutions":[{"id":"https://openalex.org/I134560555","display_name":"Universit\u00e9 Toulouse III - Paul Sabatier","ror":"https://ror.org/02v6kpv12","country_code":"FR","type":"education","lineage":["https://openalex.org/I134560555","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Maryse Lapeyre\u2010Mestre","raw_affiliation_strings":["Addictovigilance Department Toulouse University Hospital  Toulouse France","French Addictovigilance Network (FAN)  France","Inserm Unit 1027 Toulouse III University  Toulouse France"],"raw_orcid":"https://orcid.org/0000-0002-5494-5873","affiliations":[{"raw_affiliation_string":"Addictovigilance Department Toulouse University Hospital  Toulouse France","institution_ids":["https://openalex.org/I3019448017"]},{"raw_affiliation_string":"French Addictovigilance Network (FAN)  France","institution_ids":[]},{"raw_affiliation_string":"Inserm Unit 1027 Toulouse III University  Toulouse France","institution_ids":["https://openalex.org/I134560555","https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062011943","display_name":"Nathalie Fouilh\u00e9 Sam\u2010La\u00ef","orcid":"https://orcid.org/0000-0002-5620-6804","observed_orcids":["https://orcid.org/0000-0002-5620-6804"]},"institutions":[{"id":"https://openalex.org/I2800555055","display_name":"Centre Hospitalier Universitaire de Grenoble","ror":"https://ror.org/041rhpw39","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nathalie Fouilh\u00e9 Sam\u2010La\u00ef","raw_affiliation_strings":["Addictovigilance Department Grenoble Alpes University Hospital  Grenoble France","French Addictovigilance Network (FAN)  France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Addictovigilance Department Grenoble Alpes University Hospital  Grenoble France","institution_ids":["https://openalex.org/I2800555055"]},{"raw_affiliation_string":"French Addictovigilance Network (FAN)  France","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086216228","display_name":"\u00c9milie Jouanjus","orcid":"https://orcid.org/0000-0002-3510-2475","observed_orcids":["https://orcid.org/0000-0002-3510-2475"]},"institutions":[{"id":"https://openalex.org/I134560555","display_name":"Universit\u00e9 Toulouse III - Paul Sabatier","ror":"https://ror.org/02v6kpv12","country_code":"FR","type":"education","lineage":["https://openalex.org/I134560555","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Emilie Jouanjus","raw_affiliation_strings":["Addictovigilance Department Toulouse University Hospital  Toulouse France","French Addictovigilance Network (FAN)  France","Inserm Unit 1027 Toulouse III University  Toulouse France"],"raw_orcid":"https://orcid.org/0000-0002-3510-2475","affiliations":[{"raw_affiliation_string":"Addictovigilance Department Toulouse University Hospital  Toulouse France","institution_ids":["https://openalex.org/I3019448017"]},{"raw_affiliation_string":"French Addictovigilance Network (FAN)  France","institution_ids":[]},{"raw_affiliation_string":"Inserm Unit 1027 Toulouse III University  Toulouse France","institution_ids":["https://openalex.org/I134560555","https://openalex.org/I154526488"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5025705459"],"corresponding_institution_ids":["https://openalex.org/I154526488","https://openalex.org/I2800555055","https://openalex.org/I899635006"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":{"value":4200,"currency":"USD","value_usd":4200},"fwci":1.2962,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.75103842,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"88","issue":"11","first_page":"4937","last_page":"4940"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.996999979019165},{"id":"https://openalex.org/keywords/drug-abuse","display_name":"drug abuse","score":0.8989999890327454},{"id":"https://openalex.org/keywords/drug-addiction","display_name":"drug addiction","score":0.921999990940094},{"id":"https://openalex.org/keywords/ketamine","display_name":"ketamine","score":0.7630000114440918},{"id":"https://openalex.org/keywords/dextromethorphan","display_name":"dextromethorphan","score":1.0},{"id":"https://openalex.org/keywords/amantadine","display_name":"amantadine","score":0.9890000224113464},{"id":"https://openalex.org/keywords/memantine","display_name":"memantine","score":1.0},{"id":"https://openalex.org/keywords/dissociative-effects","display_name":"dissociative effects","score":0.6129999756813049},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8040000200271606},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5630000233650208},{"id":"https://openalex.org/keywords/opioid-crisis","display_name":"opioid epidemic","score":0.7139999866485596},{"id":"https://openalex.org/keywords/non-opioid-analgesics","display_name":"non-opioid analgesics","score":0.8420000076293945}],"concepts":[{"id":"https://openalex.org/C2781245242","wikidata":"https://www.wikidata.org/wiki/Q407781","display_name":"Dextromethorphan","level":2,"score":0.9299105405807495},{"id":"https://openalex.org/C2777374534","wikidata":"https://www.wikidata.org/wiki/Q409761","display_name":"Amantadine","level":2,"score":0.7689826488494873},{"id":"https://openalex.org/C2779484449","wikidata":"https://www.wikidata.org/wiki/Q412189","display_name":"Memantine","level":4,"score":0.6310655474662781},{"id":"https://openalex.org/C2780795376","wikidata":"https://www.wikidata.org/wiki/Q243547","display_name":"Ketamine","level":2,"score":0.6161699295043945},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6000615358352661},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5694687366485596},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.565249502658844},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.5301804542541504},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5284209847450256},{"id":"https://openalex.org/C2779591118","wikidata":"https://www.wikidata.org/wiki/Q659468","display_name":"Dextrorphan","level":3,"score":0.5061642527580261},{"id":"https://openalex.org/C2778767360","wikidata":"https://www.wikidata.org/wiki/Q179996","display_name":"Methadone","level":2,"score":0.4597163200378418},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.43664950132369995},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4172615110874176},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3340032696723938},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.3108043074607849},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13182801008224487},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08432191610336304},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000547","descriptor_name":"Amantadine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000700","descriptor_name":"Analgesics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001499","descriptor_name":"Bayes Theorem","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003915","descriptor_name":"Dextromethorphan","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007649","descriptor_name":"Ketamine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D008559","descriptor_name":"Memantine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014944","descriptor_name":"World Health Organization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D060735","descriptor_name":"Pharmacovigilance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/bcp.15430","doi":"https://doi.org/10.1111/bcp.15430","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15430","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9796803","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9796803","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:35665950","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35665950","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:hal-04352683v1","doi":null,"is_oa":true,"landing_page_url":"https://ut3-toulouseinp.hal.science/hal-04352683","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"British Journal of Clinical Pharmacology, 2022, 88 (11), pp.4937-4940. ⟨10.1111/bcp.15430⟩","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1111/bcp.15430","doi":"https://doi.org/10.1111/bcp.15430","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.15430","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1525436179","https://openalex.org/W1595187506","https://openalex.org/W1606744897","https://openalex.org/W1972176624","https://openalex.org/W1976601692","https://openalex.org/W2009020263","https://openalex.org/W2068026895","https://openalex.org/W2069994305","https://openalex.org/W2071828273","https://openalex.org/W2102686440","https://openalex.org/W2148622932","https://openalex.org/W2158365886","https://openalex.org/W2900651841","https://openalex.org/W2911375005","https://openalex.org/W2915077984","https://openalex.org/W3038144190","https://openalex.org/W3177475579","https://openalex.org/W3200660426"],"related_works":["https://openalex.org/W3000736751","https://openalex.org/W2168100497","https://openalex.org/W2255001689","https://openalex.org/W2059758880","https://openalex.org/W1936652454","https://openalex.org/W1983439286","https://openalex.org/W3012495265","https://openalex.org/W2267104016","https://openalex.org/W4406033282","https://openalex.org/W4297537785"],"abstract_inverted_index":{"Ketamine":[0],"and":[1,23,44,67,69,75,121,134],"dextromethorphan":[2,106],"are":[3],"widely":[4],"abused":[5],"psychoactive":[6],"substances.":[7],"Inhibition":[8],"of":[9,20,59,72,152,154],"N-methyl-d-aspartate":[10],"receptors":[11],"(NMDARs)":[12],"results":[13],"in":[14,77,158],"neurobehavioural":[15],"effects":[16],"including":[17],"hallucinations,":[18],"\"out":[19],"body\"":[21],"sensations":[22],"dissociative":[24],"effects.":[25],"However,":[26],"little":[27],"is":[28],"known":[29],"about":[30],"a":[31,47,99,128],"possible":[32],"extended":[33],"addictive":[34],"class":[35,129],"effect":[36,130],"linked":[37],"to":[38,146,149,165],"pharmacologically-related":[39],"amino-adamantane":[40],"derivatives":[41],"(e.g.,":[42],"amantadine":[43,66,116],"memantine).":[45],"Using":[46],"quasi-Bayesian":[48],"analytic":[49],"method,":[50],"we":[51],"investigated":[52,104],"the":[53,57,70,78,150,159],"potential":[54,151],"association":[55,101],"between":[56],"use":[58],"approved":[60],"NMDAR":[61,155],"antagonists":[62],"(i.e.,":[63],"dextromethorphan,":[64],"ketamine,":[65],"memantine)":[68],"reporting":[71],"drug":[73,132],"abuse":[74,133,153],"dependence":[76],"WHO":[79],"pharmacovigilance":[80],"database":[81],"(VigiBase\u00ae),":[82],"which":[83],"includes":[84],">21":[85],"million":[86],"individual":[87],"case":[88],"safety":[89],"reports":[90],"collected":[91],"from":[92],">130":[93],"countries.":[94],"This":[95,136],"disproportionality":[96],"analysis":[97],"identified":[98],"significant":[100],"for":[102,131],"all":[103],"drugs:":[105],"(IC":[107,112,117,123],"=":[108,113,118,124],"3.03":[109],"[2.97-3.09]),":[110],"ketamine":[111],"1.70":[114],"[1.57-1.83]),":[115],"0.21":[119],"[0.06-0.35])":[120],"memantine":[122],"0.27":[125],"[0.13-0.40]),":[126],"suggesting":[127],"dependence.":[135],"first":[137],"signal":[138],"requires":[139],"further":[140],"investigations,":[141],"but":[142],"health":[143],"professionals":[144],"need":[145],"be":[147],"alert":[148],"antagonists,":[156],"especially":[157],"current":[160],"\"opioid":[161],"epidemic\"":[162],"context,":[163],"due":[164],"their":[166],"growing":[167],"interest":[168],"as":[169],"non-opioid":[170],"antinociceptive":[171],"drugs.":[172]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2022-06-13T00:00:00"}